Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa
Authors:
- Cristina NovembrinoCNCristina Novembrino
- Ilaria QuagliaIQIlaria Quaglia
- Angelo Claudio MolinariAngelo Claudio Molinari
- Alessandra BorchielliniABAlessandra Borchiellini
- Antonio CoppolaACAntonio Coppola
- Rita Carlotta SantoroRita Carlotta Santoro
- Massimo Boscolo-AnzolettiMBMassimo Boscolo-Anzoletti
- Eleonora GalbiatiEGEleonora Galbiati
- Ezio ZanonEZEzio Zanon
- Alessandra ValpredaAVAlessandra Valpreda
Open Access
- 18 August 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (8) , 1999
Abstract
Recombinant porcine factor VIII (rpFVIII) is indicated for treating bleeding episodes in acquired haemophilia A, but there are few data regarding laboratory methods to adequately monitor treatment. This study involving three Italian laboratories aimed to evaluate the analytical performance of different assays for measuring rpFVIII. Five spiked rpFVIII samples (0.5–1.5 IU/mL) were analysed on three days, in triplicate, with eleven combinations of reagents (Werfen, Boston, MA, USA: SynthasIL and SynthaFax for one-stage assay, Chromogenix Coamatic FVIII for chromogenic assay), FVIII depleted plasmas (with or without von Willebrand factor—VWF) and calibrators (HemosIL human calibrator plasma, porcine calibrator diluted in FVIII deficient plasma with or without VWF). The assays were performed on ACL TOP analysers (Werfen, Boston, MA, USA). Intra- and inter-assay and inter-laboratory Coefficient of Variation (CV%) were calculated together with percentage of recovery (% recovery) on the expected value. The results showed that the reagent combinations reaching satisfactory analytical performance are: SynthasIL/human calibrator/deficient plasma+VWF (total recovery 99.4%, inter-laboratory CV 4.04%), SynthasIL/porcine calibrator/deficient plasma+VWF (total recovery 111%, inter-laboratory CV 2.75%) and Chromogenic/ porcine calibrator/deficient plasma+VWF (total recovery 96.6%, inter-laboratory CV 8.32%). This study highlights that the use of porcine standard (when available) and FVIII deficient plasma with VWF should be recommended.Keywords
This publication has 36 references indexed in Scilit:
- Mechanisms and monitoring of bypassing agent therapyJournal of Thrombosis and Haemostasis, 2012
- Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) RegistryBlood, 2012
- Porcine factor VIIIHaemophilia, 2012
- Pharmacokinetics and safety of OBI‐1, a recombinant B domain‐deleted porcine factor VIII, in subjects with haemophilia AHaemophilia, 2012
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012
- Optimization of storage conditions for diluted working solutions of porcine factor VIII and performance of the Bethesda assay for the determination of antiporcine FVIII inhibitor titresHaemophilia, 2003
- Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C)American Journal of Hematology, 2002
- Detection and Characterization of Porcine Endogenous Retrovirus in Porcine Plasma and Porcine Factor VIIIJournal of Virology, 2001
- The use of porcine factor viii in the treatment of patients with acquired hemophilia: The United Kingdom experienceThe American Journal of Medicine, 1991
- Rationale and evolution of therapy with porcine factor VIII:CThe American Journal of Medicine, 1991